

Product datasheet for **TA306633**

Glycoprotein VI (GP6) Rabbit Polyclonal Antibody

Product data:

| | |
|-----------------------|--|
| Product Type: | Primary Antibodies |
| Applications: | WB |
| Recommended Dilution: | WB: 1 ug/mL |
| Reactivity: | Human, Mouse, Rat |
| Host: | Rabbit |
| Isotype: | IgG |
| Clonality: | Polyclonal |
| Immunogen: | GPVI antibody was raised against a 18 amino acid synthetic peptide near the center of the human GPVI. The immunogen is located within amino acids 130 - 180 of GPVI. |
| Formulation: | PBS containing 0.02% sodium azide. |
| Concentration: | 1ug/ul |
| Purification: | Affinity chromatography purified via peptide column |
| Conjugation: | Unconjugated |
| Storage: | Store at -20°C as received. |
| Stability: | Stable for 12 months from date of receipt. |
| Gene Name: | glycoprotein VI platelet |
| Database Link: | NP_057447 Entrez Gene 51206 Human Q9HCN6 |




[View online »](#)

Background:

Glycoprotein VI (GP6) is a 58kD platelet membrane glycoprotein that plays a crucial role in the collagen-induced activation and aggregation of platelets. It is uniquely expressed by cells of the megakaryocytic/platelet lineage, and is a member of the immunoglobulin gene superfamily, closely related to Fc receptor gamma chain (FcR γ) and natural killer receptors. Glycoprotein VI plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcR γ , the Src kinases (likely Fyn/Lyn), the adapter protein LAT and leads to the activation of phospholipase C gamma2. GPVI deficiency can result in bleeding disorders. Further study should reveal the extent of GPVI involvement in thrombotic disease and allow the development of alternative anti-thrombotic compounds.

Synonyms:

BDPLT11; GPIV; GPVI

Product images:

Western blot analysis of GPVI expression in Jurkat cell lysate with GPVI antibody at 1ug/ml in (A) the absence and (B) the presence of blocking peptide.